Dr. Lombardi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2589 Samaritan Drive
4th Floor
San Jose, CA 95124Phone+1 408-426-4900Fax+1 669-233-2482- Is this information wrong?
Summary
- Dr. Donald Lombardi is a Medical Oncologist-Hematologist at Stanford Health Care | Cancer Center Pleasanton in Pleasanton, CA. He received his medical degree from University of Rochester School of Medicine and Dentistry and has been in practice for 30 years. He specializes in breast cancer, genitourinary oncology, and cancer genetics/cancer risk assessment, and has specialized training in cancer genomics, proteomics, and metabolomics.
Education & Training
- Scripps ResearchNone, Masters Program in Clinical and Translational Investigation, 2009 - 2011
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
- University of Michigan Health SystemResidency, Internal Medicine, 1986 - 1989
- University of Rochester School of Medicine and DentistryClass of 1986
- Bowdoin CollegeAB, Biochemistry, Magna cum laude, 1978 - 1982
Certifications & Licensure
- OR State Medical License 1996 - Present
- CA State Medical License 2007 - 2025
- ME State Medical License 2018 - 2022
- WV State Medical License 2019 - 2020
- MN State Medical License 2017 - 2019
- WA State Medical License 2009 - 2010
- TX State Medical License 2000 - 2004
- American Board of Internal Medicine Internal Medicine
- Join now to see all
Publications & Presentations
PubMed
- 202 citationsMonoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancerDaniel K. Nomura, Donald P. Lombardi, Jae Won Chang, Sherry Niessen, Anna M. Ward, Jonathan Z. Long, Heather H. Hoover, Benjamin F. Cravatt> ;Chemistry & Biology. 2011 Jul 29
- 155 citationsPhase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lap...Stephen R. D. Johnston, Maureen E. Trudeau, Bella Kaufman, Hamouda Boussen, Kimberley Blackwell, Patricia LoRusso, Donald P. Lombardi, Slim Ben Ahmed, Dennis L. Citrin...> ;Journal of Clinical Oncology. 2008 Mar 1
- EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors o...Spector NL, Blackwell K, Hurley J, Harris JL, Lombardi D, Bacus S, Ahmed SB, Boussen H, Frikha M, Ayed FB> ;J. Clin. Oncol.. 2006-06-20
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Stanford Health Care Tri-ValleyPleasanton, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: